Adenosine Receptor 3 in Liver Cancer: Expression Variability, Epigenetic Modulation, and Enhanced Histone Deacetylase Inhibitor Effects.

Saved in:
Bibliographic Details
Title: Adenosine Receptor 3 in Liver Cancer: Expression Variability, Epigenetic Modulation, and Enhanced Histone Deacetylase Inhibitor Effects.
Authors: Kaldjob-Heinrich L; Department Internal Medicine I, Eberhard-Karls University, Tuebingen, Germany., Nuciforo S; Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland.; Clinic of Gastroenterology and Hepatology, Clarunis University Center for Gastrointestinal and Liver Diseases Basel, Basel, Switzerland., Lemke S; Quantitative Biology Center (QBiC), Eberhard-Karls University, Tuebingen, Germany.; M3-Research Center for Malignome, Metabolome and Microbiome, Eberhard-Karls University, Tuebingen, Germany., Stahl A; NMI, Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany., Czemmel S; Quantitative Biology Center (QBiC), Eberhard-Karls University, Tuebingen, Germany.; M3-Research Center for Malignome, Metabolome and Microbiome, Eberhard-Karls University, Tuebingen, Germany., Babaei S; Department Internal Medicine I, Eberhard-Karls University, Tuebingen, Germany.; M3-Research Center for Malignome, Metabolome and Microbiome, Eberhard-Karls University, Tuebingen, Germany., Blukacz L; Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland., Meier MA; Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland.; Clinic of Gastroenterology and Hepatology, Clarunis University Center for Gastrointestinal and Liver Diseases Basel, Basel, Switzerland., Zhang Y; Department of Pathology and Neuropathology, Eberhard Karls University, Tübingen, Germany., Schürch CM; Department of Pathology and Neuropathology, Eberhard Karls University, Tübingen, Germany.; iFIT Cluster of Excellence EXC 2180 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard-Karls University, Tuebingen, Germany., Gonzalez-Menendez I; Department of Pathology and Neuropathology, Eberhard Karls University, Tübingen, Germany.; iFIT Cluster of Excellence EXC 2180 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard-Karls University, Tuebingen, Germany., Woelffing P; iFIT Cluster of Excellence EXC 2180 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard-Karls University, Tuebingen, Germany.; Department of Medical Oncology and Pneumology, Eberhard-Karls University, Tuebingen, Germany., Malek NP; Department Internal Medicine I, Eberhard-Karls University, Tuebingen, Germany.; M3-Research Center for Malignome, Metabolome and Microbiome, Eberhard-Karls University, Tuebingen, Germany.; iFIT Cluster of Excellence EXC 2180 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard-Karls University, Tuebingen, Germany.; Center for Personalized Medicine, Eberhard-Karls University, Tuebingen, Germany., Scheble V; Department Internal Medicine I, Eberhard-Karls University, Tuebingen, Germany., Nahnsen S; Quantitative Biology Center (QBiC), Eberhard-Karls University, Tuebingen, Germany.; M3-Research Center for Malignome, Metabolome and Microbiome, Eberhard-Karls University, Tuebingen, Germany., Claassen M; Department Internal Medicine I, Eberhard-Karls University, Tuebingen, Germany.; M3-Research Center for Malignome, Metabolome and Microbiome, Eberhard-Karls University, Tuebingen, Germany.; Department of Computer Science, University of Tübingen, Tübingen, Germany.; Machine Learning in Science, Excellence Cluster Machine Learning, University of Tübingen, Tübingen, Germany., Templin M; NMI, Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany., Bösmüller H; Department of Pathology and Neuropathology, Eberhard Karls University, Tübingen, Germany., Heim MH; Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland.; Clinic of Gastroenterology and Hepatology, Clarunis University Center for Gastrointestinal and Liver Diseases Basel, Basel, Switzerland., Dauch D; iFIT Cluster of Excellence EXC 2180 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard-Karls University, Tuebingen, Germany.; Department of Medical Oncology and Pneumology, Eberhard-Karls University, Tuebingen, Germany., Bitzer M; Department Internal Medicine I, Eberhard-Karls University, Tuebingen, Germany.; M3-Research Center for Malignome, Metabolome and Microbiome, Eberhard-Karls University, Tuebingen, Germany.; iFIT Cluster of Excellence EXC 2180 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard-Karls University, Tuebingen, Germany.; Center for Personalized Medicine, Eberhard-Karls University, Tuebingen, Germany.
Source: Gastro hep advances [Gastro Hep Adv] 2024 Nov 20; Vol. 4 (3), pp. 100590. Date of Electronic Publication: 2024 Nov 20 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Inc on behalf of the AGA Institute Country of Publication: Netherlands NLM ID: 9918350485906676 Publication Model: eCollection Cited Medium: Internet ISSN: 2772-5723 (Electronic) Linking ISSN: 27725723 NLM ISO Abbreviation: Gastro Hep Adv Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2772-5723
DOI:10.1016/j.gastha.2024.11.006